Skip to main content

Advertisement

Table 2 Adverse event (AE; %) within placebo groups, by type of AE (where at least three reviews reported the same AE)

From: Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials

  Amanzio, 2009 Mahr, 2017a Mahr, 2017b Rief, 2006 Rief, 2009 Rojas-Mirquez, 2014 Median (IQR)
Aa Bb Cc     TCA SSRI   
Abdominal pain 2.97 1.04 1.04 6.8 3.3   8.4 9 5.68 4.5 (2.5–7.2)
Burning 5.88 1.83 8.7        5.9 (3.9–7.3)
Chest discomfort/pain 0 0.8   4.2   0.82     0.8 (0.6–1.7)
Chills 1.4 0.47 3.7        1.4 (0.9–2.6)
Diarrhea   1.25 3.51 7.7   3.53     3.5 (2.9–4.6)
Dry mouth 4.26 1.75 3.11 5.1    19.2 6.4   4.7 (3.4–6.1)
Dyspepsia 1.13 1.46 3.21 3.9   2.03     2.0 (1.5–3.2)
Fatigue 2.85 1.47 8.72 9.3    17.3 5.5   7.1 (3.5–9.2)
Insomnia    0 5.7    13.3 11.1 4.73 5.7 (4.7–11.1)
Paresthesia 1.1 0.88 6.58 3.6       2.4 (1.0–4.3)
Somnolence 1.05 2.76 5.67     16.8 6.8 5.44 5.6 (3.4–6.5)
Taste disturbance 1.06 1.34 4.1       1.3 (1.2–2.7)
Vomiting/nausea 8.9 4.38 2.11 7.7 4.9 2.55 12 10.5 8.18 7.7 (4.4–8.9)
Headache     9.9   10.59 27.4 19.9 18.01 18.0 (10.6–19.9)
Dizziness     5.1   1.81    5.5 5.1 (3.5–5.3)
Eye disorders     1.4    6.9 1.2   1.4 (1.3–4.2)
Constipation     6   6.85 10.7 4.2   6.4 (5.6–7.8)
  1. aNSAID
  2. bTriptans
  3. cAnti-convulsant